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older adults with type 2 diabetes: study protocol
for a randomized controlled trial
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and Caryl A Nowson1Abstract
Background: While physical activity, energy restriction and weight loss are the cornerstone of type 2 diabetes
management, less emphasis is placed on optimizing skeletal muscle mass. As muscle is the largest mass of
insulin-sensitive tissue and the predominant reservoir for glucose disposal, there is a need to develop safe and
effective evidence-based, lifestyle management strategies that optimize muscle mass as well as improve glycaemic
control and cardiometabolic risk factors in people with this disease, particularly older adults who experience
accelerated muscle loss.
Methods/Design: Using a two-arm randomized controlled trial, this 6-month study builds upon the
community-based progressive resistance training (PRT) programme Lift for Life® to evaluate whether ingestion of a
whey-protein drink combined with vitamin D supplementation can enhance the effects of PRT on glycaemic
control, body composition and cardiometabolic health in older adults with type 2 diabetes. Approximately 200
adults aged 50 to 75 years with type 2 diabetes, treated with either diet alone or oral hypoglycaemic agents (not
insulin), will be recruited. All participants will be asked to participate in a structured, supervised PRT programme
based on the Lift for Life® programme structure, and randomly allocated to receive a whey-protein drink (20 g daily
of whey-protein plus 20 g after each PRT session) plus vitamin D supplements (2000 IU/day), or no additional
powder and supplements. The primary outcome measures to be collected at baseline, 3 and 6 months will be
glycated haemoglobin (HbA1c) and insulin sensitivity (homeostatic model assessment). Secondary outcomes will
include changes in: muscle mass, size and intramuscular fat; fat mass; muscle strength and function; blood pressure;
levels of lipids, adipokines and inflammatory markers, serum insulin-like growth factor-1 and 25-hydroxyvitamin D;
renal function; diabetes medication; health-related quality of life, and cognitive function.
(Continued on next page)* Correspondence: rmdaly@deakin.edu.au
1Centre for Physical Activity and Nutrition Research, Deakin University,
Melbourne, VIC, Australia
Full list of author information is available at the end of the article
© 2014 Daly et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Daly et al. Trials 2014, 15:431 Page 2 of 12
http://www.trialsjournal.com/content/15/1/431(Continued from previous page)
Discussion: The findings from this study will provide new evidence on whether increased dietary protein achieved
through the ingestion of a whey-protein drink combined with vitamin D supplementation can enhance the effects
of PRT on glycaemic control, muscle mass and size, and cardiometabolic risk factors in older adults with type 2
diabetes.
Trial registration: Australian New Zealand Clinical Trials ACTRN12613000592741.
Keywords: Older adults, Progressive resistance training, Randomized controlled trial, Study protocol,
Type 2 diabetes, Vitamin D, Whey-proteinBackground
Type 2 diabetes is one of the most prevalent chronic
metabolic diseases of the twenty-first century [1,2]. In
2011, there were 366 million people with diabetes glo-
bally, a figure projected to rise to 552 million by 2030
[3]. The human and economic burden of illness associ-
ated with type 2 diabetes contributes significantly to ill
health, disability and premature death, and is further ex-
acerbated by the onset of micro- and macrovascular
complications. Thus, there is a need to develop safe, ef-
fective and sustainable population-based prevention and
management strategies that collectively improve multiple
risk factors associated with this disease.
Lifestyle modification combining energy restriction,
weight loss and physical activity remains the cornerstone
of type 2 diabetes prevention and treatment [4,5]. While a
reduction in body weight and improvements in glycaemic
control have been observed following energy restriction
and aerobic or endurance activity, a concomitant loss in
muscle mass can also occur [6,7]. Skeletal muscle is crit-
ical for people with type 2 diabetes, as it is the largest mass
of insulin-sensitive tissue and the predominant reservoir
for glucose disposal. Losses in muscle mass can nega-
tively impact metabolic rate, compound the problems of
insulin resistance and lead to reduced physical function
and quality of life [8,9]. As a result, current international
consensus exercise guidelines recommend that progres-
sive resistance training (PRT) be incorporated into the
overall physical activity plan for people with type 2 dia-
betes, owing to its positive effects on muscle mass and
glycaemic control [5]. Indeed, our previous research has
demonstrated that high-intensity PRT is safe and effect-
ive for improving glycated haemoglobin (HbA1c) levels
and lean tissue mass in older adults with type 2 diabetes
[10-12]. This work led to the development of a national
community-based PRT programme, entitled Lift for Life®
[13], with the goal of providing greater access for adults
with, or at risk, of type 2 diabetes, to participate in an
evidence-based PRT programme within existing commu-
nity health and fitness centres through the development
of a network of accredited providers [14].
Since nutritional management is also an important com-
ponent in the treatment of type 2 diabetes, combiningPRT with dietary modification may offer a synergistic
and incremental effect on glycaemic control as well as
body composition and cardiometabolic risk factors.
While the optimal macronutrient composition of the diet
for the management of type 2 diabetes remains uncer-
tain, emerging evidence suggests that there are health
benefits associated with high-protein diets in overweight
and obese adults and those with type 2 diabetes. For in-
stance, a meta-analysis of nine randomized controlled
trials ranging from 4 to 24 weeks reported that high-
protein diets had beneficial effects on weight loss and
HbA1c levels and tended to reduce blood pressure in
people with type 2 diabetes, with no adverse effects on
blood lipids [15]. Despite these positive findings, dietary
studies controlling for macronutrient composition are
often difficult to implement in the ‘real-world’, as they
require an individual to follow a prescribed meal plan,
and adherence often relies on self-reported dietary in-
take. Therefore, the addition of a protein supplement
might be a more practical and effective approach, as it
does not require individuals to make marked changes in
their usual dietary habits. This approach was used in a
study of overweight and obese adults and showed that a
daily intake of greater than 30% energy from protein
achieved through a whey-protein supplement, compared
with a diet containing approximately 16% of energy from
protein through habitual intake, was more effective for
improving lipid levels and insulin sensitivity [16]. Im-
portantly, energy intakes remained similar between the
groups throughout the study, and there was no effect of
the intervention on body composition. A number of
other short-term studies have also reported that whey-
protein has insulinotropic properties that can improve
insulin sensitivity and glycaemic control in people with
type 2 diabetes [17-19].
In non-diabetic adults, there is compelling evidence
that ingestion of whey-protein soon after exercise can
augment the anabolic benefits of PRT on muscle mass
[20,21]. While there is still ongoing research into defin-
ing whether there is an optimal dose of protein needed
to elicit a synergistic skeletal muscle response with PRT,
particularly in older adults, several recent studies and re-
views have recommended that 20 to 40 g of high-quality,
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protein, be consumed soon after each bout of PRT to
maximally stimulate muscle protein synthesis and pro-
mote muscle hypertrophy [22-24]. Given that skeletal
muscle is the primary site of glucose disposal, and is
highly responsive to exercise as a stimulus to increase
glucose uptake, we hypothesize that combining PRT
with whey-protein might represent an optimal strategy
to enhance muscle hypertrophy and glycaemic control,
and improve cardiometabolic risk factors in people with
type 2 diabetes.
There are also other lifestyle factors that might have
beneficial effects on skeletal muscle. For instance, there
is mounting evidence that treatment with vitamin D can
have positive effects on muscle, including strength and
function [25,26]. Low serum 25-hydroxyvitamin D (25
(OH)D) levels might also play a role in the development
of type 2 diabetes [27,28], with reports that vitamin D
deficiency is associated with impaired β-cell function,
glucose intolerance and insulin resistance [28]. Although
the findings from randomized controlled trials examin-
ing the effects of supplemental vitamin D, alone or with
calcium, on measures of glycaemic control, insulin sensi-
tivity and secretion have been inconclusive, there is
some evidence for a beneficial effect in adults with or at
increased risk of type 2 diabetes [29-32]. There are also
reports that vitamin D might have anti-inflammatory
properties, particularly in people with various patho-
logical conditions, such as type 2 diabetes [33,34]. This
is important because chronic low-grade inflammation
has been linked to accelerated muscle loss and has
emerged as the common denominator linking type 2
diabetes, metabolic syndrome, insulin resistance, en-
dothelial dysfunction and cardiovascular disease [28].
While the optimal serum 25(OH)D concentration for
muscle and health benefits remains hotly debated, we
hypothesize that vitamin D treatment combined with
whey-protein supplementation and PRT will be more
effective for improving glycaemic control, body compos-
ition and various inflammatory and cardiovascular risk
factors in people with type 2 diabetes than PRT alone.
The primary aim of this randomized controlled trial is
to examine whether a community-based PRT programme
combined with additional whey-protein and vitamin D
can promote greater improvements in glycaemic control
and insulin sensitivity than PRT alone in older adults
with type 2 diabetes. Secondary aims of the study are to
assess the effects of the intervention on changes in: (1)
total body and regional lean tissue mass and fat mass,
thigh muscle cross-sectional area and muscle density (as
a surrogate measure of intramuscular fat infiltration),
muscle strength and functional performance; (2) cardio-
vascular risk factors, including blood pressure and blood
lipid levels, (3) levels of adipokines and inflammatorymarkers, and (4) quality of life and cognitive function. In
addition, we will examine whether changes in lean tissue
mass, muscle size, density and strength and a reduction
in metabolic or inflammatory markers are predictive of




This study is a 6-month, two-arm, parallel, randomized
controlled trial. Participants with confirmed type 2 dia-
betes will be asked to participate in a structured PRT
programme, based on the community-based Lift for Life®
programme, and randomly allocated to receive either a
whey-protein powdered drink plus vitamin D supp-
lements, or no additional powder or supplements. A
matched placebo powder was deemed inappropriate for
this trial, as the use of food additives, such as maltodex-
trin, has the potential to influence the outcome mea-
sures (for example, glycaemic control). The selection of
a two-arm design (for example, the lack of a true ‘non-
exercise’ control arm) is consistent with our primary
research aim, which seeks to examine whether whey-
protein plus vitamin D can enhance the health benefits of
PRT in older adults with type 2 diabetes. The trial is man-
aged by the Centre for Physical Activity and Nutrition
Research at Deakin University, Burwood, Melbourne,
Victoria, Australia and is funded by a National Health and
Medical Research Council Project Grant (ID1046269).
The study has been approved by the Deakin University
Human Research Ethics Committee (HREC 2013–050),
and is registered with the Australian and New Zealand
Clinical Trials Registry (ACTRN12613000592741).
Participants
Men and women aged 50 to 75 years with established
type 2 diabetes, treated with diet alone or any oral
hypoglycaemic agents (except insulin), will be invited to
participate in the study.
Recruitment
Participants living in the Melbourne metropolitan and
surrounding areas in Victoria, Australia with type 2 dia-
betes will be recruited into the study via state and local
media campaigns, including newspaper and radio adver-
tisements, flyers, web-based media and word of mouth.
This will be further supplemented with letters sent to
local doctors, endocrinologists, pharmacists, diabetic ed-
ucators and support groups, asking them to place adver-
tisements in their facilities and inviting them to refer
patients with type 2 diabetes to the study. A letter will
also be sent to participants with type 2 diabetes who are
registered on the National Diabetes Services Scheme,
which is an initiative of the Australian Government
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trial. All participants who express an interest in the study
will undergo screening to determine their eligibility to
participate in the trial based on the outlined criteria.
Screening and eligibility
Eligibility for the study will be based on a two-step
screening process. First, all participants will be screened
via a telephone questionnaire and ineligibility will be
based on the following criteria: (1) HbA1c >10%; (2)
current or prior participation in a structured PRT
programme >1 session per week or moderate-intensity
physical activity ≥150 min/week in the previous 3 months;
(3) vitamin D or calcium supplement use >500 IU/day
and >600 mg/day, respectively, in the previous 3 months;
(4) severe orthopaedic, cardiovascular or respiratory
conditions that would preclude participation in an exer-
cise programme, or those with absolute contraindica-
tions to exercise, according to American College of
Sports Medicine guidelines [35]; (5) renal impairment
(eGFR <45 ml/(min 1.73 m2)) or disease; (6) regular use
of protein supplements; (7) conditions that may affect
vitamin D or calcium metabolism; (8) current smoker,
or (9) body mass index >40 kg/m2. Participants will be
encouraged and monitored to keep constant throughout
the study any use of lipid-lowering or anti-hypertensive
medication and not modify their lifestyle habits other
than necessary for the study. To increase the external
validity of the study and because of a lack of consensus
with regard to the optimal serum 25(OH)D concen-
tration for health benefits, vitamin D status will not be
an inclusion or exclusion criterion but will be assessed as
part of the biochemical analysis. Data from the 1999 to
2000 Australian Diabetes, Obesity and Lifestyle (AusDiab)
study, involving more than 11,000 Australians, indicates
that 89% of adults with type 2 diabetes had insufficient
serum 25(OH)D levels (<75 nmol/l) and 55% were vita-
min D deficient (<50 nmol/l) (RMD, unpublished ob-
servation). Participants who pass the initial telephone
screening will be required to obtain approval from their
local doctor to clear them of any contraindicated med-
ical conditions to exercise, based on American College
of Sports Medicine guidelines, to participate in the
programme. Participants will also be asked to provide a
fasted, morning blood sample to confirm that their
HbA1c level is <10%. Written informed consent will be
obtained from all participants prior to commencing the
programme.
Randomization and blinding
Following completion of baseline testing, participants will
be randomized, stratified by sex and diabetes treatment
(diet or oral hypoglycaemic agents), in blocks of four
using a computer-generated random number sequenceby an independent researcher. All research staff involved
in the assessments will be blinded to the group alloca-
tion. The programme coordinator will be solely respon-
sible for the distribution of the protein powder and
vitamin D supplements. A flow diagram of the study
protocol is outlined in Figure 1.
Intervention
Progressive resistance training programme
All participants involved in the study will be asked
to complete 24 weeks of resistance training (64 sessions
in total), based on the successful Lift for Life® PRT
programme, in community-based health and fitness
centres. The Lift for Life® programme is a structured,
evidence-based PRT programme that is designed for
people with, or at risk, of developing type 2 diabetes.
It has been developed from a series of previous labora-
tory and community-based exercise intervention studies
demonstrating that PRT is safe and effective for improv-
ing glycaemic control and body composition in people
with type 2 diabetes [10-12]. The programme will con-
sist of moderate to high-intensity PRT (three sets of
eight to ten repetitions at a weight that cannot be lifted
for more than eight to ten repetitions) involving dynamic
concentric and eccentric contractions targeting all the
major muscle groups and with an emphasis on weekly
progressive overload (increments of 2 to 10%). Partici-
pants will train twice a week for the first 8 weeks, and
three times weekly for the remainder of the programme.
Training sessions will last 45 to 60 minutes and will be
supervised by qualified trainers (accredited exercise phys-
iologists, physiotherapists and experienced Certificate
IV personal trainers). All participants enrolled in the
study will be charged a fee by each local provider to
undertake the 24-week programme, at a cost of approxi-
mately Australian $5 to $13 per session, but will be eli-
gible for reimbursement up to the value of Australian
$240 at the completion of the study based on their level
of exercise compliance (for example, 80% compliance will
equate to a $192 rebate).
The 24-week Lift for Life® PRT programme is divided
into three phases (bronze, silver, gold), each 8 weeks in
duration. During the initial phase (bronze), participants
receive education on the benefits of the programme,
safety and correct exercise techniques and are asked to
attend two supervised exercise sessions per week. After
8 weeks, all programmes will be reviewed and a new
customized programme will be designed for each partici-
pant (silver), but with the aim of participating in one
additional unsupervised exercise session to achieve the
goal of three PRT sessions per week. The final 8-week
phase (gold) is a replication of the previous phase with a
new customized and progressively challenging programme.
Throughout the programme, all completed exercises,
® ® 
Figure 1 Flow diagram of progress from screening to the final follow-up assessment.
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Lift for Life® exercise cards, to monitor progression and
compliance. Further details of the programme, including
examples of the exercises and intensity prescribed, have
been reported previously [14].
One of the challenges when implementing exercise
programmes in community settings is that of enhancing
adoption and adherence to these programmes. At the
foundation of Lift for Life® and central to its success are in-
dividually tailored PRT programmes and supervised
training sessions. The supervised sessions serve two pur-
poses. First, the programme aims to emulate the level of
attention received by participants in the previous trials on
which the exercise guidelines and Lift for Life® programme
are based. Second, previous research demonstrates that
unsupervised training is less effective in translating to
health benefits [12,36]. Exercise programmes prescribed
as part of the Lift for Life® programme are individually
tailored, so comorbidities or complications (for example,
knee osteoarthritis) can be taken into consideration with
exercises appropriately modified on a case-by-case basis.
Further, to enhance compliance and retention, all partici-
pants will receive monthly follow-up phone calls, andwill be eligible to receive a reimbursement (as indicated
previously) to cover the costs associated with their par-
ticipation in the programme.
Whey-protein drink and vitamin D supplementation
Participants randomized to the protein and vitamin D
group will receive a 3-month supply of a whey-protein
enriched powder and vitamin D supplements at their
baseline testing appointment and again after 12 weeks.
The protein powder will be provided in a single-use sachet
form (OmniBlend, Campbellfield, Victoria, Australia). Par-
ticipants will be instructed to add 150 ml of cold water to
a calibrated ‘shake-and-take’ container and then add one
sachet (powder) containing 20 g of whey-protein concen-
trate 80%, containing approximately 2.4 g of leucine, to
the water, close the lid and shake vigorously for at least
ten shakes and consume immediately. Participants will be
instructed to consume one drink every morning before
breakfast and one drink within two hours of each PRT
session. Thus, they will consume a total of seven drinks
per week, with an extra drink on each of the two training
days during the first 8 weeks. This will increase to ten
drinks per week when participants move to three sessions
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dose from 20 g on non-training days to 40 g on training
days. Each protein drink will provide approximately
335 kJ of energy, 2 g of lactose, 1 g of fat and 5 g of fibre.
Participants will also be asked to take two 1000 IU
capsules of Vitamin D3 (Ostelin, Melbourne, Victoria,
Australia) every evening for the duration of the study.
The goal of vitamin D treatment is to raise serum 25
(OH)D concentrations to at least 75 nmol/l. All supple-
ments and the protein powder will be provided free of
charge.
Outcome measures
A summary of the proposed outcome measures is shown
in Table 1. Participants will attend Deakin UniversityTable 1 Summary of the outcome measures
Variables Data collection method
Primary outcome measures
Glycated haemoglobin (HbA1c) Overnight, fasted serum sample
HOMA-2 insulin resistance Overnight, fasted serum sample, HO
HOMA-2 β-cell function Overnight, fasted serum sample, HO
Secondary outcome measures
Body composition Dual energy X-ray absorptiometry tot
fat mass, and bone density
Peripheral quantitative computed to
Biochemistry and hormonal measures Routine biochemistry
Serum 25-hydroxyvitamin D
Adipokines and inflammatory markers Overnight fasted plasma collection
Blood lipids Overnight fasted plasma collection
Blood pressure Automated measurement
Muscle strength Leg press and seated row
Isometric knee extensor strength
Muscle function and balance Timed up-and-go test
Four-square step test
30-second sit-to-stand test
Diabetes and other medication Monthly reports
Health-related quality of life Short Form (36) version 2 questionn
Cognitive function CogState Brief Battery computerized
Additional measures
Anthropometry Height, weight, body mass index an
Physical activity Community Healthy Activities Model
Diet Anti-Cancer Council Food Frequenc
24-hour food recollection
Adverse events Monthly phone calls
Programme adherence Calculated from monthly calendars
Supplement compliance Calculated from supplement and sach
HOMA, homeostasis model assessment.twice throughout the duration of the study for assess-
ment (at baseline and after 24 weeks), with an intermedi-
ary assessment of anthropometry, muscle strength,
physical and cognitive function and repeat questionnaires
conducted on-site at each health and fitness centre after
12 weeks. With the exception of the fasted blood sample
collection, which will occur at local pathology clinics at
baseline, 12 and 24 weeks, and the intermediary assess-
ment, all other outcome measures will be assessed within
the School of Exercise and Nutrition Sciences at Deakin
University, Burwood, Melbourne, Victoria, Australia.
Primary outcome measures
The primary outcome measures will be changes in
glycated haemoglobin levels (HbA1c) and homeostasisData collection points
Baseline 3 months 6 months
× × ×
MA-2 calculator × × ×
MA-2 calculator × × ×
al body and regional lean mass and × ×












aire × × ×
tests × × ×
d waist circumference × × ×
Program for Seniors questionnaire × × ×
y questionnaire × ×
× × ×
Collected from monthly calls
collected every 8 weeks Collected every 8 weeks
ets returned at 3 and 6 months × ×
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β-cell function based on model-derived estimates using
the validated HOMA-2-calculator [37], version 2.2.3,
from fasting glucose and insulin measured at least three
days after the last PRT session. All data will be checked
prior to importing into the calculator, and extreme
values of fasting plasma glucose ≤3 or ≥25 mmol/l or
serum insulin <20 or >300 pmol/l will be excluded, as
this is the validity range of the HOMA-2 calculation,
based on specific insulin measures. More specific details
of the blood collection and methodology for assessing
these measures are provided later.
Secondary outcome measures
Secondary outcome measures will include changes in:
body composition (lean tissue mass, muscle size and
intramuscular fat), fat mass, muscle strength, blood pres-
sure, blood lipids, adipokines and inflammatory markers,
serum insulin-like growth factor-1 and 25(OH)D, renal
function, diabetes medication (purpose, variety and dos-
age), health-related quality of life and cognitive function.
Other covariates and variables of interest to be assessed
include: anthropometry, habitual physical activity, diet
and use of lipid-lowering and blood pressure medication.
A summary of all the outcome measures is shown in
Table 1.
Body composition Total body and regional (arms and
legs) lean tissue mass, fat mass and percentage body fat
will be assessed using dual energy X-ray absorptiometry
(Lunar Prodigy, GE Lunar Corp., Madison, WI, USA),
using software version 12.30.008. A peripheral quantita-
tive computed tomography scanner (XCT 3000, Stratec
Medizintechnik GmbH, Pforzheim, Germany) will be
used to measure muscle cross-sectional area, subcutane-
ous fat cross-sectional area and muscle density, as a sur-
rogate measure of intermuscular adiposity, at the 25%
femur site using methods previously reported [38].
Briefly, after performing a scout view of the distal end of
the femur, scans will be taken at the 4% and 25% position
of the femur. The slice thickness will be 2.3 mm, and the
voxel size will be set at 0.3 mm at a scanning speed of
10 mm/s. Subcutaneous fat cross-sectional area will be
determined by selecting the area with thresholds −40
to +40 mg/cm3 hydroxyapatite density (contour mode 3,
peel mode 1), and the muscle cross-sectional area will be
determined by subtracting the total bone cross-sectional
area (threshold, 280 mg/cm3; contour mode 1, peel mode
2) and subcutaneous fat cross-sectional area from the
total area of the distal femur (threshold, −40 mg/cm3,
contour mode 3, peel mode 1). For consistency, all ana-
lysis of dual energy X-ray absorptiometry and peripheral
quantitative computed tomography will be undertaken
by a single investigator. The short-term coefficient ofvariation for repeated measurements of total body lean
mass and fat mass in our laboratory ranges from 1.0% to
1.7%. The coefficient of variation for the femur muscle
cross-sectional area is 1.3%.Biochemical, hormonal and inflammatory markers
Following an overnight fast, participants will attend one
commercial pathology clinic with multiple collection
centres where rested, morning (8 to 10 am) venous
blood samples will be collected. All blood will be sent to
a central pathology laboratory accredited by the National
Association of Testing Authorities Royal College of
Pathologists Australasia. HbA1c will be assessed by cation
exchange HPLC using a Bio-Rad VARIANT II turbo
HbA1c kit-2.0 (Bio-Rad Laboratories, Hercules, CA, USA).
Fasting plasma glucose will be assessed using the hexoki-
nase method (Roche Diagnostics, Mannheim, Germany).
Levels of C-peptide will be assessed using an electroche-
miluminescence immunoassay and of high sensitivity C-
reactive protein by an Immunoturbidimetric assay from
Roche Diagnostics (Mannheim, Germany). Total choles-
terol, high-density lipoprotein cholesterol and triglycer-
ides will be determined using an enzymatic colorimetric
method (Roche Diagnostics, Mannheim, Germany). Low-
density lipoprotein cholesterol will be calculated using
Friedewald’s formula. Serum creatinine, urea, albumin,
calcium and phosphorus levels will be analyzed using
standardized techniques. The estimated glomerular fil-
tration rate (eGFR), as a measure of kidney function,
will be calculated using the participants’ serum creatin-
ine, age and sex according to the abbreviated ‘modifica-
tion of diet in renal disease’ formula, which is now used
by most laboratories in Australia:
eGFR (ml/(min 1.73 m2) = 175 × [serum creatinine
(μmol/l) × 0.0113]–1.154 × age (years)-0.203] for men and
eGFR (ml/(min 1.73 m2) = 175 × [serum creatinine
(μmol/l) × 0.0113]–1.154 × age (years)-0.203 × 0.742 for
women.
Serum aliquots will also be collected and stored at
−80°C so that the following parameters can be assessed
in a single batch at the completion of the study: levels
of serum insulin, serum 25(OH)D, serum insulin-like
growth factor 1, serum adiponectin and resistin, and a
battery of pro-inflammatory and anti-inflammatory cyto-
kines, including IL-6, IL-1β, IL-8, TNF-α and IL-10.Blood pressure After a 5-minute rest period seated in a
quiet room, systolic and diastolic blood pressure will be
measured using an automated blood pressure monitor
(A&D Instruments, Oxon, UK). Four measurements will
be taken on the left arm with a 2-minute interval be-
tween readings; the mean of the final three readings will
be used in the analysis.
Daly et al. Trials 2014, 15:431 Page 8 of 12
http://www.trialsjournal.com/content/15/1/431Muscle strength Muscle strength of the lower limbs
and upper back will be measured by employing a three-
repetition maximum strength test for leg press and
seated row exercises. This test determines the heaviest
weight that can be used to complete three complete rep-
etitions of an exercise whilst maintaining correct form
and technique, and corresponds to ≈ 85% of an indi-
vidual’s one-repetition maximum strength. Prior to the
three-repetition maximum muscle strength test, par-
ticipants will complete a 5-minute warm-up on an exer-
cise bike. To determine the three-repetition maximum
strength, each participant will initially perform a warm-
up set of eight to ten repetitions with a light load. After
successful completion of a further six to eight repetitions
at a heavier weight selected by the instructing researcher
and following a brief rest (≈2 to 3 minutes), the work-
load will be increased incrementally until only three rep-
etitions with correct technique can be completed. For
each participant, the formula employed by Wathen et al.
[39] will be used to calculate each participant’s leg and
back one-repetition maximum strength. In addition, iso-
metric knee extensor strength will be measured on the
participant’s dominant leg using Lord’s strap assembly,
incorporating a strain gauge (Neuroscience Research
Australia, Sydney, New South Wales, Australia). Parti-
cipants will have one practice trial followed by two max-
imal tests with a 60 second rest between each test. This
test has been shown to have excellent test-retest reliabil-
ity (Pearson’s r = 0.92) [40]. For analysis, knee extension
strength will be expressed per unit of lower leg length to
compensate for the length of the lever arm.
Physical function The timed up-and-go test, four-
square step test and 30-second sit-to-stand test will be
used to assess muscle function.
The timed up-and-go test is a measure of dynamic bal-
ance during three commonly performed functional activ-
ities: standing up from and sitting down in a chair,
walking, and turning [41]. Briefly, participants will be
seated in a chair (height 45 cm) that will be placed at
the end of a marked 3 m walkway. On the command
‘go’, participants will be instructed to stand up, walk at a
comfortable speed for 3 m, turn, walk back to the chair
and sit down. To minimize any ceiling effects and make
the test more challenging, the participants will also be
instructed to start counting backwards in threes from a
random number. All participants will be given a practice
trial and one test run. A stopwatch will be used to rec-
ord the time taken (in seconds) to complete the test.
This test has an established interrater reliability, with an
intraclass correlation of 0.99 [42].
The four-square step test is a clinical test used to as-
sess dynamic standing balance and stepping speed in
four different directions [43]. This test has been shownto have high interrater (intraclass correlation, 0.99) and
retest reliability (intraclass correlation, 0.98) [43]. To
complete this test, participants will be required to step
forwards, sideways and backwards over four canes rest-
ing flat on the floor in a cross formation, moving first in
a clockwise and then in a counterclockwise direction to
return to the starting position. Participants will be
instructed to complete the task as quickly as possible
without touching or stepping on the canes, and if pos-
sible, to face forwards during the entire sequence. They
will also be instructed to ensure that both feet make
contact with the floor in each square. After one practice
trial, participants will complete the test and the time (in
seconds) taken to complete the sequence will be mea-
sured with a stopwatch and recorded as the final score.
The 30-second sit-to-stand test provides a measure of
lower-extremity muscle strength and function and is
administered in a chair without arms [44]. Participants
start from a seated position in the chair, with arms
folded across the chest, and are instructed to stand fully
upright and then return to the seated position at their
own pace as many times as possible in 30 seconds. The
final score will be the number of complete stands re-
corded during this time. This test has been shown to
have good reliability with a test-retest intraclass correl-
ation of 0.84 to 0.92 in a community-dwelling sample of
older men and women aged 60 years and over [44].Dietary habits The Anti-Cancer Council Food Fre-
quency questionnaire will be used to quantify habitual
eating habits and provide data on macro- and micronu-
trient intake [45]. Dietary data collected from the Anti-
Cancer Council Food Frequency questionnaire will be
supplemented with 24-hour dietary recollections com-
pleted at baseline, 12 and 24 weeks. Participants will be
contacted (via phone) by the research staff (trained in
completing food recall tasks) and asked to report all
food and drink consumed over the previous 24-hour
period. A standard script will be used and the ‘triple
pass’ method will be utilized to maximize the ability of
respondents to recall what was consumed. Household
measures (measuring cups, plates, bowls and glasses)
will be used to help estimate food portion sizes and par-
ticipants will be provided with a standard portion size
booklet. The data collected from the 24-hour recalls will
be entered and analyzed using Australia-specific dietary
analysis software (FoodWorks, Xyris software, Highgate
Hill, Queensland, Australia).Anthropometry Height will be measured to the nearest
0.1 cm with a wall-mounted stadiometer and body
weight to the nearest 0.1 kg using calibrated electronic
digital scales. Waist circumference will be measured on
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eral border of the right iliac crest.
Physical activity Total leisure and recreational physical
activity time (hours per week) will be assessed using the
Community Healthy Activities Model Program for Se-
niors physical activity questionnaire. This questionnaire
has been specifically designed for use in older adults and
found to be reliable, valid and sensitive to change [46].
Participants will document the frequency and duration
of their participation in a ‘typical week’ of the preceding
four weeks. The results will be reported as estimated ki-
lojoules per week spent in moderate to high-intensity
activities.
Health and medical history and medication use All
participants will complete a lifestyle questionnaire to
obtain information on education background, current
and previous employment details, history of diseases or
illnesses, family history of diabetes, smoking history,
current medication and dietary supplement use, average
weekly alcohol consumption, weekly television viewing
and sitting time, and sun exposure habits. For women,
menstrual history, including age of onset of menopause
and menstrual cycle regularity, together with use of oral
contraceptive and hormone replacement therapy will be
evaluated. Information on any alterations to or new
medication prescribed by the participants’ doctors will
also be collected by research staff via the monthly phone
calls. Information recorded will include medication
name, dose prescribed and daily quantity taken.
Health-related quality of life Health-related quality of
life will be assessed using the Short Form (36) version 2
questionnaire, which is a general measure of health sta-
tus including eight scales: physical functioning, physical
role functioning, bodily pain, general health perceptions,
vitality, social role functioning, emotional role function-
ing and mental health [47]. This test yields a score from
0 to 100, where 0 represents the lowest and 100 repre-
sents the highest quality of life. Reliability scores of
above 0.80 and empirical validities of 0.80 to 0.90 have
been reported in the literature for both the physical and
mental health measures [47].
Cognitive function Cognitive function will be assessed
using the CogState Brief Battery computerized tests [48],
which provide sensitive and valid measurement of a
range of different cognitive functions [49,50]. The bat-
tery of tests that will be used for this study include: mea-
sures of executive function and spatial problem solving
(Groton maze learning test), psychomotor function and
speed of processing (detection task), visual attention (iden-
tification task), visual learning with a pattern separationmodel (one-card learning task) and working memory and
attention (one-back task). Specific details about these five
tests have been described previously [49-52]; all tests
have been designed for repeated administration with
minimal practice or learning effects.
Compliance Compliance in taking the prescribed pro-
tein and vitamin D will be evaluated via self-completed
compliance calendars and cross-referenced by counting
remaining sachets and vitamin D capsules returned at
each subsequent follow-up appointment. Compliance
with the exercise programme will be evaluated via self-
completed exercise cards, which will be initialled by the
participant and viewed (signed off ) by the trainer after
each session and collected by the research staff from
each health and fitness centre at approximately two-
monthly intervals throughout the intervention.
Adverse events Any adverse events associated with the
exercise programme or supplements will be recorded by
the research staff during the monthly phone calls to par-
ticipants. For this study, an adverse event is defined as
any health-related unfavourable or unintended medical
occurrence (sign, symptom, syndrome, illness) that de-
velops or worsens during the period of observation in
the trial. All adverse events will be assessed for serious-
ness, causality and expectedness by the research staff
and recorded and monitored during the trial.
Sample size calculations
The sample size is based on the following power calcula-
tions from previously published studies of PRT in older
adults (including those with type 2 diabetes) [10-12,36,38],
and work of others that have assessed the independent or
combined effects of protein, vitamin D and PRT on the
outcome measures [16,29,53,54]. It was estimated that
168 participants would provide 90% power (P <0.05 two-
tailed test) to detect a 0.5% difference for the change in
HbA1c levels between the groups, assuming a conserva-
tive standard deviation of 1.1%. For insulin sensitivity, a
sample size of 140 would be required to detect a 0.7 dif-
ference for the change in HOMA-2 insulin resistance
between the groups at a power of 90%, assuming a con-
servative standard deviation of 1.2. To compensate for a
projected 20% drop-out, a total of 202 participants will
be recruited to the study and randomized 1:1 to the two
groups (101 participants per group).
Statistical analysis
The primary statistical analyses will be conducted on an
intention-to-treat basis using STATA statistical software
release 12.0 (STATA, College Station, TX, USA). Per-
protocol analysis will also be performed by including all
participants who are at least 80% compliant in completing
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sessions attended) and in taking the drinks and supple-
ments (as measured from the compliance calendar and
pill count). Baseline characteristics between the groups
will be compared by independent t tests for continuous
variables and chi-square tests for categorical variables.
Wherever possible, we will obtain endpoint measures
from all withdrawals and include all randomized subjects
in our final data analysis. All data will be checked for nor-
mality prior to analysis, and skewed data will be log
transformed prior to analysis. Time, group and group-by-
time interactions will be examined using generalized
linear mixed models with random effects. Potential
covariates to be included in the model will include: age,
sex, race or ethnicity, changes in medication and change
in habitual physical activity or diet. Multiple regression
analysis will be used to investigate whether changes in
lean tissue mass, muscle size, density and strength and a
reduction in metabolic or inflammatory markers are pre-
dictive of any exercise-induced improvements in gly-
caemic control and insulin sensitivity. All data will be
presented as mean ± standard deviation or 95% con-
fidence intervals. The significance level will be set at
P <0.05 or smaller if adjustments are made for multiple
comparisons.
Discussion
This study will be the first randomized controlled trial in
older adults with type 2 diabetes to investigate whether
increased dietary protein achieved through the ingestion
of a whey-protein drink combined with vitamin D sup-
plementation can enhance the effects of PRT on gly-
caemic control, muscle mass and cardiometabolic risk
factors. This is important because most current lifestyle
approaches for the treatment of type 2 diabetes focus on
general physical activity (typically aerobic training) and
calorie restriction to manage body weight. While such
approaches have been shown to improve glycaemic con-
trol, blood pressure and lipid levels and reduce weight
and fat mass, they are often associated with a loss in lean
tissue (muscle) mass [6,7]. Given that skeletal muscle is
the largest mass of insulin-sensitive tissue and the pre-
dominant reservoir for glucose disposal, there is a need
to develop, evaluate and disseminate approaches that are
safe and effective for optimizing muscle mass as well as
glycaemic control and other cardiometabolic related risk
factors in people with this disease, particularly older
adults with type 2 diabetes who experience an acceler-
ated loss in muscle mass with age [55].
Progressive resistance training is one strategy that is
now widely recommended for people with type 2 dia-
betes because of its beneficial effects on muscle mass,
glycaemic control and other cardiometabolic risk factors
that contribute to the development of diabetes and itscomplications. In non-diabetic adults, there is a growing
body of evidence that post-exercise ingestion of a protein-
rich source, such as whey-protein, can maximize the ana-
bolic benefits of PRT on muscle [20-24]. Moreover, there
is evidence that supplementation with vitamin D can
have beneficial effects on muscle and measures of insulin
sensitivity and secretion [25-28]. Therefore, this study
will provide new information as to whether combining
PRT with additional protein and vitamin D can promote
a synergistic and incremental effect on glycaemic control,
muscle mass and cardiometabolic risk factors compared
with PRT alone in older adults with type 2 diabetes. If
successful, this study will broaden the knowledge base
and contribute to best practice guidelines on exercise
and nutrition for the treatment of type 2 diabetes, along
with the ongoing refinement of community-based initia-
tives for the management of this condition. In addition,
the findings from this study will provide evidence to
inform policy and translational activities of the existing
community-based Lift for Life® programme, which is
currently implemented throughout Australia.
Trial status
Recruitment is currently underway and a number of par-
ticipants have commenced the study.
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